Everything below concerns bremelanotide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
=== 21st century === In the past decade, documenting forensics scenes has become more efficient. Forensic scientists have started using laser scanners, drones and photogrammetry to obtain 3D point clouds of accidents or crime scenes. Reconstruction of an accident scene on a highway using drones involves data acquisition time of only 10–20 minutes and can be performed without shutting down traffic. The results are not just accurate, in centimeters, for measurement to be presented in court but also easy to digitally preserve in the long term. Now, in the 21st century, much of forensic science's future is up for discussion. The National Institute of Standards and Technology (NIST) has several forensic science-related programs: CSAFE, a NIST Center of Excellence in Forensic Science, the National Commission on Forensic Science (now concluded), and administration of the Organization of Scientific Area Committees for Forensic Science (OSAC). One of the more recent additions by NIST is a document called NISTIR-7941, titled "Forensic Science Laboratories: Handbook for Facility Planning, Design, Construction, and Relocation". The handbook provides a clear blueprint for approaching forensic science. The details even include what type of staff should be hired for certain positions.
== History == OHPH was first described, along with hydroxyprogesterone caproate and hydroxyprogesterone acetate, by Karl Junkmann of Schering AG in 1954. It was introduced for medical use by 1957. OHPH was commercialized by Roussel and Théramex, and has been used clinically in France and Monaco but is no longer marketed.
AnIML Core AnIML Technique Definitions Additionally, AnIML Technique Definition Documents apply constraints to the AnIML Core and are specified by the AnIML Technique Definitions. The AnIML Core consists of a set of rules defining the structure of the XML document, providing a universal container for arbitrary analytical data. AnIML Technique Definitions describe how to use the AnIML Core to record experiments of a particular scientific discipline. There is a big similarity between the mechanisms of AnIML and the AVI format. The AnIML Core defines the data container, whereas the AnIML Technique Definitions act similar to the AVI codec. It defines how the data needs to be structured and labeled. Technique Definitions are XML documents, specified by the Technique Schema. official website AnIML on GitHub
Nucleic acid tertiary structure is the three-dimensional shape of a nucleic acid polymer. RNA and DNA molecules are capable of diverse functions ranging from molecular recognition to catalysis. Such functions require a precise three-dimensional structure. While such structures are diverse and seemingly complex, they are composed of recurring, easily recognizable tertiary structural motifs that serve as molecular building blocks. Some of the most common motifs for RNA and DNA tertiary structure are described below, but this information is based on a limited number of solved structures. Many more tertiary structural motifs will be revealed as new RNA and DNA molecules are structurally characterized.
Sources: en.wikipedia.org
All patients were switched to or continued their treatments only with gemigliptin 50 mg qd during the extension period. A further decrease in HbA1c was observed in the continued treatment with gemigliptin 50 mg in this extension period, and the mean change from baseline at 52 weeks (–0.87%) was still clinically and statistically significant (full analysis set analysis, P<0.0001). In another blinded, active-controlled, phase III trial (study identifier: LG-DPCL011), eligible patients with HbA1c greater than 7.5% were randomized to receive gemigliptin 50 mg qd with metformin slow release (SR) qd (n=141), gemigliptin 50 mg qd (n=142), or metformin SR qd (n=150) for 24 weeks. After 24 weeks, the reduction from the baseline in HbA1c was –1.24% for gemigliptin monotherapy. In a meta-analysis involving data from 10 randomized controlled trials (1,792 patients), Dutta et al. demonstrated the good glycaemic efficacy, durability and safety of gemigliptin in managing type-2 diabetes Initial combination therapy with metformin In this randomized, blinded, active-controlled, phase III trial (study identifier: LG-DPCL011, INICOM study; ClinicalTrials.gov registration number: NCT01787396), eligible patients with an HbA1c greater than 7.5% were randomized to gemigliptin 50 mg qd+metformin SR qd (n=141), gemigliptin 50 mg qd (n=142), or metformin SR qd (n=150). From weeks 2 to 6, metformin SR was uptitrated incrementally from 500 to 2,000 mg/day maximum in the gemigliptin/metformin and metformin groups.
[...] if the Russian Federation's Ministry of Defense did not publish such data [indicating the timeline of Russian military activities], then the suspicion grows elsewhere that perhaps they are covering something up such as the exact times they moved." Thomas contended that it was "likely" Saakashvili did not intend to use force "until he was cornered by events." Thomas stated that analysts saw the Russian activities in Abkhazia before August 2008 "as a deception operation to draw attention away from preparations underway in South Ossetia." Thomas criticized the Russian research The Tanks of August because it "omitted crucial meetings and attempts of Georgia to avoid conflict and none of the events were documented with footnotes." Thomas noted, "Russia refused to negotiate with Georgia in the crucial days before conflict erupted. [...] Artillery duels were heavier than in the past, and some artillery positions were located behind Russian peacekeeping forces in South Ossetia." Thomas further stated, "The conclusion that many analysts have reached is that the actions of the Russians were preplanned and that they drew the Georgians into a decision dilemma: either act or lose territory. [...] One of the problems with the Russian version of events is that it ignores all of the positive things Georgia did to prevent fighting from ever breaking out." In 2012, Rick Fawn and Robert Nalbandov wrote that "the precise timing of events on the night of 7–8 August 2008 is a substantial study in itself, and depends on all of the inputs being provable.
Peripheral nerves are more likely to be damaged, but the effects of the damage are not as widespread as seen in injuries to the spinal cord. Treatments are currently in clinical trials to repair severed nerves, with early success. Stem cells induced to a neural fate injected in to a severed nerve. Within four weeks, regeneration of previously damaged stem cells and completely formed nerve bundles were observed. Stem cells are also in clinical phases for treatment in ophthalmology. Hematopoietic stem cells have been used to treat corneal ulcers of different origin of several horses. These ulcers were resistant to conventional treatments available, but quickly responded positively to the stem cell treatment. Stem cells were also able to restore sight in one eye of a horse with retinal detachment, allowing the horse to return to daily activities.
Sources: en.wikipedia.org
== Deaths == 2 March - Robert Watkin Wynne, politician, 52? 12 April - Evan Davies, Independent minister, 56 19 September - John Roberts, hymn-writer, 75 October - Gabriel Jones, Welsh American lawyer and politician, 82 4 October - Samuel Horsley, Bishop of St Asaph date unknown Fulke Greville, former MP for Monmouth Boroughs
Although Fredrickson claims that her experimental results are still valid, these experimental results have also been questioned due to poor statistical methodology, and Alan Sokal has pointed out that "given [Fredrickson and Losada's] experimental design and method of data analysis, no data whatsoever could possibly give any evidence of any nonlinearity in the relationship between "flourishing" and the positivity ratio — much less evidence for a sharp discontinuity." Another study surveyed a U.S. sample of 3,032 adults, aged 25–74. Results showed 17.2 percent of adults were flourishing, while 56.6 percent were moderately mentally healthy. Some common characteristics of a flourishing adult included: educated, older, married and wealthy. The study findings suggest there is room for adults to improve as less than 20 percent of Americans are living a flourishing life. (Keyes, 2002). Benefits from living a flourishing life emerge from research on the effects of experiencing a high ratio of positive to negative affect. The studied benefits of positive affect are increased responsiveness, "broadened behavioral repertoires", increased instinct, and increased perception and imagination. In addition, the good feelings associated with flourishing result in improvements to immune system functioning, cardiovascular recovery, lessened effects of negative affect, and frontal brain asymmetry.
== Safety == Cyanuric acid is classified as "essentially nontoxic". The 50% oral median lethal dose (LD50) is 7700 mg/kg in rats. However, when cyanuric acid is present together with melamine (which by itself is another low-toxicity substance), it will form an insoluble and rather nephrotoxic complex, as evidenced in dogs and cats during the 2007 pet food contamination and in children during the 2008 Chinese milk scandal cases.
=== The analyte is adsorbed onto the electrode surface === Adsorbed species give simple voltammetric responses: ideally, at slow scan rates, there is no peak separation, the peak width is 90mV for a one-electron redox couple, and the peak current and peak area are proportional to scan rate (observing that the peak current is proportional to scan rate proves that the redox species that gives the peak is actually immobilised). The effect of increasing the scan rate can be used to measure the rate of interfacial electron transfer and/or the rates of reactions that are coupltransfer. This technique has been useful to study redox proteins, some of which readily adsorb on various electrode materials, but the theory for biological and non-biological redox molecules is the same (see the page about protein film voltammetry).
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.